Participated · Series C · Oct 2025

Hemab Therapeutics is focused on creating prophylactic, antibody-based treatments that address the underlying causes of serious bleeding disorders rather than just managing acute events. Its lead asset, sutacimig (formerly HMB-001), has completed Phase 2 in Glanzmann thrombasthenia and is being prepared for a registration study in 2026, with a parallel Phase 2 program planned for Factor VII deficiency. The company’s second clinical candidate, HMB-002, targets the C-terminal CK domain of Von Willebrand Factor to raise endogenous VWF and Factor VIII levels and is advancing toward registration studies in Von Willebrand disease. Backed by its “Hemab 1-2-5” strategy, the team is also moving additional programs forward, with HMB-003 expected to enter the clinic in the first half of 2026. Hemab’s dual headquarters in Cambridge, Massachusetts, and Copenhagen, Denmark, give it access to both U.S. and European scientific ecosystems. The fresh Series C financing provides $157 million to fund late-stage trials, expand the pipeline, and reinforce the company’s goal of becoming “the ultimate clotting company.”

Led · Series A · Dec 2024

Ottimo Pharma is advancing bifunctional medicines with a lead asset, Jankistomig, a first‑in‑class PD1/VEGFR2 bifunctional antibody being developed in both IV and SC forms. The company is conducting IND‑enabling studies for Jankistomig and plans to file an IND in late 2025. Ottimo emerged from stealth in October 2024 and was co‑founded by Medicxi and Jonny Finlay in 2020. The program is positioned to target immune checkpoint inhibition and angiogenesis simultaneously, aiming to offer a wider therapeutic window regardless of tumor VEGF levels. Management has been strengthened with senior hires in finance, technical/quality, and legal functions to support clinical and CMC advancement. The company highlights a potential addressable global oncology market valued at well over $50 billion and has secured substantial Series A funding to progress its pipeline.

Participated · Series B · May 2021

Nuvalent is a Cambridge, Mass.-based biotechnology company creating precisely targeted small-molecule therapies against clinically validated kinase targets in cancer. The company leverages structure-based design to develop selective inhibitors intended to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC—NVL-520 (ROS1-selective) and NVL-655 (ALK-selective)—alongside multiple discovery-stage research programs. It plans to use the proceeds from its financing for clinical advancement of NVL-520 and NVL-655 and to expand and accelerate its discovery research pipeline. The company announced leadership additions including CEO James Porter, Ph.D., and Chief Medical Officer Christopher Turner, M.D., and expects Andrew Hack of Bain Capital Life Sciences to join its board following the financing. Nuvalent closed a $135M Series B financing. Nuvalent is a Cambridge, MA-based biotechnology company creating precisely targeted small-molecule therapies for clinically proven kinase targets in cancer. The company leverages structure-based drug design to develop selective kinase inhibitors intended to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent has launched a portfolio of kinase inhibitors with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer, including NUV-520 (a potential best-in-class ROS1-selective inhibitor) and NUV-655 (an ALK-selective inhibitor). It also maintains multiple discovery-stage research programs advancing its proprietary discovery efforts. The founding technology was developed under the guidance of Matthew Shair, Ph.D., who serves as Founder and Head Scientific Advisor, and James R. Porter, Ph.D., is CEO. Financially, the company completed a $50M Series A financing with an investment from Deerfield Management.

Led · Series C · Mar 2021

Monte Rosa Therapeutics has built a platform to rationally design small-molecule molecular glues that hijack ubiquitin ligases to eliminate disease-driving proteins previously deemed undruggable. The platform combines proprietary chemical libraries with in-house proteomics, structural biology, machine learning-based target selection (including prediction of degrons) and computational chemistry. The company intends to advance its lead development candidate into the clinic and prepare IND-enabling studies later this year. Proceeds from the recent financing will also be used to accelerate pipeline growth and bolster platform capabilities to expand targeted programs. Monte Rosa positions its approach to address genomically defined diseases, including cancers driven by undruggable proteins. The company was launched from Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston with research operations in Boston and Basel, Switzerland. Monte Rosa Therapeutics develops small-molecule degraders—molecular glues—that hijack the body’s protein-degradation machinery to remove disease-causing proteins. The company closed a $96 million Series B to accelerate growth of its pipeline and bolster its platform capabilities. Monte Rosa plans to build out its platform while concurrently advancing a portfolio of drug candidates for multiple indications, including cancer. One portfolio lead, MRT-048, has shown a differentiated degradation profile and promising in vivo activity in several models of resistant breast cancer and is undergoing further preclinical development and safety testing. The company expects to file one or more IND submissions during 2021. Monte Rosa was launched by Ridgeline, Versant’s Discovery Engine in the Technologiepark Basel, in collaboration with The Institute of Cancer Research and Cancer Research UK, and it has offices and labs in Basel and Boston. Monte Rosa Therapeutics develops a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The platform combines computational modeling of ligase-neosubstrate interactions, quantitative proteomics, structural biology, and a diverse chemical library of protein degraders. The company was launched in 2018 from Versant’s Ridgeline Discovery Engine and is headquartered in Boston with research operations in Boston and Basel, Switzerland. Several validated small-molecule leads, including MRT-048, have demonstrated novel degradation profiles and in vivo efficacy across tumor models; MRT-048 is undergoing further preclinical development and safety testing. Monte Rosa plans to expand its chemical library (projected to exceed 10,000 structures by the end of 2020), advance multiple drug candidates, file one or more IND submissions during 2021, and explore discovery-stage pharma collaborations. The company disclosed a $32.5 million Series A commitment and intends to launch a Series B to back the development of multiple clinical-stage programs.

Participated · Series C · Feb 2021

Vividion Therapeutics is a biotechnology company that uses integrated discovery technologies to enable precision small‑molecule therapeutics for oncology and immunology. Its platform finds cryptic functional pockets, uses a proteome‑trained covalent chemistry library, and applies industrial‑scale chemoproteomics to ensure selectivity. Leveraging these capabilities, Vividion is advancing a broad pipeline of potent, selective small molecules across oncology and immune indications. The company’s initial wholly owned programs target the KEAP1‑NRF2 axis (both antagonists for NRF2 mutant/addicted cancers and agonists for inflammatory diseases) and, in partnership with Bristol Myers Squibb, a program against a challenging transcription factor. Vividion says it intends to begin advancing programs into the clinic next year. The company is headquartered in San Diego. Vividion Therapeutics is a San Diego-based biotechnology company with a platform to discover small molecule therapeutics against biologically compelling but previously intractable targets. Its platform, built on seminal work from labs at The Scripps Research Institute, enables screening of small molecules against every protein in native biological systems and identifies highly selective binders agnostic to protein class and function. Those binders can be developed into drugs using approaches including direct and allosteric modulation of protein function and targeted protein degradation. The company’s immediate focus is in oncology and immunology. Led by CEO Dr. Diego Miralles, Vividion intends to use new funding to expand operations and advance its research efforts. Vividion Therapeutics has developed a chemical proteomics platform that creates proteome-wide drug interaction maps to identify ligands and targets in native biological systems. The platform is designed to expand the druggable proteome and address targets previously considered undruggable by assessing target engagement and global selectivity early. Vividion applies novel chemistry to accelerate optimization of fragment hits into drug candidates and holds a robust intellectual property estate covering newly recognized druggable sites. The company was spun out of labs at The Scripps Research Institute and was founded with seed financing from Cardinal Partners. Headquartered in San Diego, Vividion focuses on developing transformative therapeutics to treat major unmet clinical needs. In conjunction with its launch financing, the company added experienced industry leadership to its board to support accelerated drug discovery and development.